ADC Landscape
AbbVie (ImmunoGen)
FRα · Platinum-resistant ovarian cancer
ApprovedAntibody–Drug Conjugates
Target
FRα
Payload
DM4
Payload class
Maytansinoid
Linker
Cleavable (sulfo-SPDB)
Indication
Platinum-resistant ovarian cancer
Phase
Approved
Partner
— (AbbVie acq. ImmunoGen $10B)
Overview
First ADC to show an OS benefit in ovarian cancer, biomarker-selected by folate-receptor-α expression. Anchored AbbVie's $10B ImmunoGen acquisition.
Technology
AbbVie (ImmunoGen) works in Antibody–Drug Conjugates — A guided missile: an antibody that flies a chemo warhead straight to the tumor.
Read the Antibody–Drug Conjugates brief →Related companies
Daiichi Sankyo
HER2
Gilead
TROP2
AstraZeneca / Daiichi
TROP2
Pfizer (Seagen)
CD30
Pfizer (Seagen)
Nectin-4
Pfizer (Seagen)
Tissue Factor
Company website / source ↗ Open the interactive map →
◢ Boom-cycle briefing
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.
Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.